CAR 70/IL15-transduced CB-NK Cells Therapy(MD Anderson Cancer Center)

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameCAR 70/IL15-transduced CB-NK Cells Therapy(MD Anderson Cancer Center)
Drug Alias NameCAR.70- Engineered IL15-transduced Cord Blood-derived NK Cell Therapy
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Cytokine-induced killer cell > Chimeric antigen receptor CIK cell therapyCell and gene therapy > Cell therapy > Source of cells > Umbilical cord blood-derived
Mechanisms of ActionImmunomodulators
TargetsUpdating
Therapy Area/IndicationsMyelodysplastic SyndromesMultiple MyelomaCarcinoma, Renal Cell +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesMultiple MyelomaCarcinoma, Renal Cell +[12] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A